Injection pen market seen reaching $103.59 billion by 2030

The injection pen market is projected to grow from $61.17 billion in 2025 to $67.94 billion in 2026, driven by rising diabetes and other chronic diseases, along with wider use of self-administered therapies. The Business Research Company says the market could hit $103.59 billion by 2030 as smart pens, reusable devices and connected drug-delivery tools gain traction.

Why it matters: - Injection pens are becoming a core drug-delivery format for chronic disease care because they make self-administration simpler, more accurate and more convenient than vial-and-syringe methods. - Faster adoption matters for diabetes, arthritis and other long-term conditions where consistent dosing and at-home treatment can improve adherence. - The market’s projected growth signals rising demand for patient-friendly devices and connected delivery tools across global healthcare systems.

What happened: - The Business Research Company projected the global injection pen market will rise from $61.17 billion in 2025 to $67.94 billion in 2026. - The forecast implies an 11.1% compound annual growth rate. - The market is projected to reach $103.59 billion by 2030, also at an 11.1% CAGR. - North America was the largest regional market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company published a free sample of the report here. - The full report is available here.

The details: - Injection pens typically include a medication cartridge, a dial for dose measurement and a disposable needle. - The devices are designed to administer medication beneath the skin. - The report links historical growth to rising diabetes and other chronic diseases, more self-administration therapies, broader use of biologic drugs, improved pen design and stronger patient preference for pen-based delivery. - Expected growth drivers include higher demand for home-based drug administration, wider acceptance of smart injection pens, chronic disease management initiatives, sustainability efforts and innovation in connected drug delivery. - Emerging trends include more user-friendly devices, more disposable and prefilled pens, better dose accuracy and safety features, more reusable and rechargeable pens and improved tools to support patient adherence. - April 2025 International Diabetes Federation data showed 589 million adults aged 20 to 79 were living with diabetes worldwide. - The International Diabetes Federation estimates that figure will rise to 853 million by 2050.

Between the lines: - The forecast points to a market shift from basic delivery devices toward smarter, more connected and more sustainable formats. - The emphasis on home treatment suggests healthcare providers and device makers are responding to pressure for lower-cost, more convenient care outside clinical settings. - Diabetes remains the clearest demand engine, but the report also signals broader use across chronic disease management as populations age and obesity rates climb.

What's next: - The market is expected to keep expanding through 2030 if smart pens, reusable formats and connected dosing tools continue gaining adoption. - Device makers are likely to focus on dose accuracy, safety, adherence support and sustainability to capture growth. - Regional growth opportunities will vary by territory as adoption rates differ across the markets covered in the report.

The bottom line: - Injection pens are moving from a convenience product to a major chronic-care delivery platform, and the market outlook suggests that shift is far from over.